Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 914
  • Home
  • Print this page
  • Email this page

   Table of Contents      
CASE REPORT
Year : 2020  |  Volume : 68  |  Issue : 4  |  Page : 653-656

Convergence excess consecutive esotropia associated with 0.01% atropine eye drops usage in patients operated for intermittent exotropia


1 Department of Pediatric Refractive Errors, Jyotirmay Eye Clinic for Children and Adult Squint and Ocular Motility Laboratory, Thane; Department of Pediatric Ophthalmology, Mahatme Eye Hospital, Nagpur, Maharashtra, India
2 Department of Pediatric Refractive Errors, Jyotirmay Eye Clinic for Children and Adult Squint and Ocular Motility Laboratory, Thane, Maharashtra, India
3 Department of Pediatric Ophthalmology, Mehta Eye Clinic, Mumbai, Maharashtra, India

Date of Submission10-Jul-2019
Date of Acceptance08-Oct-2019
Date of Web Publication16-Mar-2020

Correspondence Address:
Dr. Mihir Kothari
Jyotirmay Eye Clinic for Children and Adult Squint, Ocular Motility Lab and Pediatric Low Vision Center, 104, 105 Kaalika Tower, Kolbad Road, Khopat, Thane West - 400 601, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_1243_19

Rights and Permissions
  Abstract 


To report convergence excess esotropia (CEET) following 0.01% atropine eye drops (Low dose atropine [LDA]). Children who developed CEET that resolved promptly after discontinuation of LDA are described. Three myopes aged 5.3 ± 1.2 years and mean sphere -4.5D were included. All were operated for intermittent exotropia earlier. Mean esotropia was +28.3PD for near and 10.6PD for distance. LDA induced high AC/A ratio and fusion normalized in 3 weeks after discontinuation of LDA. LDA should be used with caution in patients with esophoria or previously operated for intermittent exotropia. Any evidence of the emergence of a CEET should warrant discontinuation of LDA.

Keywords: Anticholinergic, atropine, convergence excess, esotropia, progressive myopia


How to cite this article:
Kothari M, Modak M, Khan H, Jahan S, Solanki M, Rathod V. Convergence excess consecutive esotropia associated with 0.01% atropine eye drops usage in patients operated for intermittent exotropia. Indian J Ophthalmol 2020;68:653-6

How to cite this URL:
Kothari M, Modak M, Khan H, Jahan S, Solanki M, Rathod V. Convergence excess consecutive esotropia associated with 0.01% atropine eye drops usage in patients operated for intermittent exotropia. Indian J Ophthalmol [serial online] 2020 [cited 2020 Apr 4];68:653-6. Available from: http://www.ijo.in/text.asp?2020/68/4/653/280702



According to recent studies, 0.01% atropine eye drop (LDA) has become popular first-line treatment for progressive childhood myopia.[1],[2] In spite of +3D to +6D decrease in accommodation with LDA, hypoaccommoadtion is seldom of any clinical concern.[3],[4]

In this study, we present hitherto unreported complication of LDA induced convergence excess esotropia (CEET) due to hypoaccommodation following its application once at night. The esotropia promptly normalized and the fusion was restored in all the children after discontinuation of LDA.


  Case Reports Top


Patient 1: A 6-year-old boy, who underwent bilateral lateral rectus recession of 7.5 mm and inferior oblique weakening for basic type intermittent exotropia with V-pattern, a year prior to starting LDA, developed CEET following its use. His esotropia measured +18PD for distance and +35 PD for near that reduced to +14PD esophoria for distance and +16 PD esophoria for near after discontinuing LDA [Figure 1] and [Table 1]. Peripheral fusion was found to be restored on Bagolini striated glasses. Prior to the use of LDA, he had orthotropia for the near, flick esotropia (+4PD) for the far, and peripheral fusion was present.
Figure 1: Picture of 6-year-old boy with 0.01% atropine induced esotropia in the left eye (a) and resolution after stopping (b)

Click here to view
Table 1: Clinical profile of the patients who developed esotropia with LDA

Click here to view


Patient 2: A 6-year-old girl, already on LDA, underwent bilateral lateral rectus recession of 7 mm for intermittent exotropia with tenacious proximal fusion. She was orthotropic for near and +8PD esotropic for distance postoperatively. The LDA was discontinued on the day of surgery and resumed 2 weeks post-surgery; post 1 month of following she developed +2PD esotropia for distance and +25PD for near that recovered to orthotropia after its discontinuation [Figure 2] and [Table 1]. Her fusion was also restored.
Figure 2: Picture of 6-year-old girl with 0.01% atropine induced esotropia in the right eye (a) and resolution after discontinuation (b)

Click here to view


Patient 3: A 4-year-old girl using LDA for 3 months, underwent left eye lateral rectus recession of 7.5 mm and medial rectus resection of 5 mm with bilateral inferior oblique weakening for basic type intermittent exotropia with V-pattern. Postoperatively she had orthotropia for distance and +4PD esotropia for near. She resumed LDA 2 weeks after surgery. One month later, she developed +12PD esotropia for distance and +25PD esotropia for near. Three weeks after stopping LDA, her near esotropia was reduced to +12PD [Figure 3] and peripheral fusion was restored.[Figure 3]
Figure 3: Picture of 4-year-old girl with 0.01% atropine induced esotropia in the left eye (a), an immediate resolution with +3.0D add (b) and resolution after discontinuation (c)

Click here to view


LDA was effective in retarding the myopia progression in all the patients [Figure 4].
Figure 4: Line diagram demonstrating the effectiveness of 0.01% atropine (LDA) in patients with CEET

Click here to view


Accommodation improved in patient 1 and patient 2 after stopping LDA [Table 2]. However, binocular and monocular accommodative functions could not be measured in patient 3.
Table 2: Improvement in accommodative functions after cessation of 0.01% atropine eye drops in patients with convergence excess esotropia

Click here to view



  Discussion Top


A modest reduction in accommodation in children using LDA is common and generally well tolerated.[2],[3],[4],[5],[6] However, the accommodative abnormalities induced due to long-term use of LDA may affect accommodation and convergence relationship resulting in CEET in children, especially with pre-existing fusional anomalies.

In our study, bedtime instillation of LDA in the patients, who were monofixators postoperatively, resulted in hypoaccommodation induced excessive innervational drive to accommodate, leading to manifest esotropia with an increased AC/A ratio causing decompensation of their tenuous fusion. Similarly, a previous study by Lyu, et al.[7] reported a median increase of +10PD in 38% of children with pre-existing esodeviation under the effect of partial cycloplegia using 0.5% tropicamide and 0.5% phenylephrine. A maximum increase of +25PD was reported which recovered after the effect of cycloplegia subsided. A similar phenomenon (CEET) was observed with the use of systemic anticholinergics viz. scopolamine patch for sialorrhoea in cerebral palsy,[8] amitriptyline and oxybutynin for nocturnal enuresis,[9],[10],[11] and haloperidol and benzatropine mesylate for Tourette syndrome.[12]

The AC/A ratio is believed to be inborn and remains constant throughout life but varies greatly amongst individuals.[13] Cycloplegic agents interfere with accommodation but if it is retained due to incomplete cycloplegia, it induces a reflex convergence by excessive innervational accommodative effort, thus increasing esodeviation.[14] Conversely, if cycloplegia is complete and present for an extended duration, accommodative efforts are suspended causing complete abolition of an accommodative component of esotropia. This is typically seen with the use of 1% atropine drops in patients with fully refractive accommodative esotropia [Figure 5].[15]
Figure 5: Picture of 5-year-old girl with fully refractive accommodative esotropia in the left eye (a) and resolution after extended and complete cycloplegia produced with 1% atropine eye ointment (b)

Click here to view


Some factors that were common in all our patients and previous studies were 1) pre-existing esophoria and 2) prompt reduction in esotropia after discontinuation of the drops. Although two patients in our study were left with significant esotropia, future follow-ups may show a further reduction of esotropia provided their LDA is stopped. Inability to recognize this side effect of LDA could cause permanent contracture of medial rectus leading to incomplete resolution of esotropia despite its discontinuation. Such a phenomenon is often reported in presbyopes, which could happen due to defects in vergence adaptation (neurologic) or muscle length adaptation (anatomic).[16] Because the children were young, no forced duction test (FDT) was performed on medial rectus. Inference of a positive FDT is that the long-term use of LDA caused muscle length adaptation (medial rectus shortening) in response to increased accommodative effort induced convergence excess.

Although none of our patients had convergence excess type of intermittent exotropia preoperatively, it is advisable to discontinue LDA in such patients scheduled for squint surgery.

The last point of contention is possible therapeutic use of LDA for patients with low AC/A ratio viz. convergence insufficiency. Similar to once used cholinergic agents viz echothiopate, carbachol, and isfoflurophate for convergence excess esotropia, it is possible that LDA may improve AC/A ratio in patients with convergence insufficiency. This question is best left for future research.

To summarize, LDA should be used cautiously and after a detailed discussion with the parents regarding it's off label use for retardation of myopia progression more so in the patients having pre-existing fusional anomalies (or other ocular comorbidity). Any evidence of the development of a CEET or any other side effect should warrant immediate discontinuation of LDA. Further research is needed to determine whether bifocal glasses or progressive addition lenses with LDA or switching to 1% atropine eye drops could prevent a recurrence of CEET while retaining the therapeutic benefits of atropine.[17],[18]

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Kesarwani SS; Mumbai Group of Paediatric Ophthalmologists and Strabismologists. Consensus statement and guidelines for use of dilute atropine sulphate in myopia control. Indian J Ophthalmol 2019;67:461-3.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for treatment of childhood myopia: Safety and efficacy of 0.5%, 0.1% and 0.01% doses. Ophthalmology 2012;119:347-54.  Back to cited text no. 2
    
3.
Cooper J, Eisenberg N, Schulman E, Wang FM. Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci 2013;90:1467-72.  Back to cited text no. 3
    
4.
Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: Myopia control with atropine 0.01% eye drops. Ophthalmology 2016;123:391-9.  Back to cited text no. 4
    
5.
Nishiyama Y, Moriyama M, Fukamachi M, Uchida A, Miyaushiro H, Kurata A, et al. Side effects of low dose atropine. Nippon Ganka Gakkai Zasshi 2015;119:812-6.  Back to cited text no. 5
    
6.
Loughman J, Flitcroft DI. The acceptability and visual impact of 0.01% atropine in a Caucasian population. Br J Ophthalmol 2016;100:1525-9.  Back to cited text no. 6
    
7.
Lyu IJ, Park KA, Oh SY. Increase in esodeviation under cycloplegia with 0.5% tropicamide and 0.5% phenylephrine mixed eye drops in patients with hyperopia and esotropia. BMC Ophthalmol 2017;17:247.  Back to cited text no. 7
    
8.
Good WV, Crain LS. Esotropia in a child treated with a scopolamine patch for drooling. Pediatrics 1996;97:126-7.  Back to cited text no. 8
    
9.
Cioplean ED, Camburu LR. Transitory consecutive esotropia after amitriptyline treatment for nocturnal enuresis -case report. Rom J Ophthalmol 2015;59:116-8.  Back to cited text no. 9
    
10.
Wong EY, Harding A, Kowal L. Oxybutynin-associated esotropia. J AAPOS 2007;11:624-5.  Back to cited text no. 10
    
11.
Kaneko K, Fujinaga S, Ohtomo Y, Shimizu T, Yamashiro Y. Combined pharmacotherapy for nocturnal enuresis. Pediatric Nephrol 2001;16:662-4.  Back to cited text no. 11
    
12.
Oh SY, Shin BS, Lee YH, Lee AY, Kim JS. Benztropine-induced esotropia and mydriasis. J Neuroophthalmol 2007;27:312-3.  Back to cited text no. 12
    
13.
Christoferson KW, Ogle KN. The effect of homatropine on the accommodation-convergence association. AMA Arch Ophthalmol1956;55:779-91.  Back to cited text no. 13
    
14.
Morgan MW, Peters HB. Accommodative convergence in presbyopia. Am J Optom 1951;28:3-6.  Back to cited text no. 14
    
15.
Kothari M, Manurung F, Paralkar S. Use of atropine to predict the accommodative component in esotropia with hypermetropia. Indian J Ophthalmol 2011;59:487-90.  Back to cited text no. 15
[PUBMED]  [Full text]  
16.
Wright WW, Gotzler KC, Guyton DL. Esotropia associated with early presbyopia caused by inappropriate muscle length adaptation. J AAPOS 2005;9:563-6.   Back to cited text no. 16
    
17.
Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006;113:2285-91.  Back to cited text no. 17
    
18.
Kothari M, Rathod V. Efficacy of 1% atropine eye drops in retarding progressive axial myopia in Indian eyes. Indian J Ophthalmol 2017;65:1178-81.  Back to cited text no. 18
[PUBMED]  [Full text]  


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
 
  Search
 
    Similar in PUBMED
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Case Reports
Discussion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed308    
    Printed0    
    Emailed0    
    PDF Downloaded66    
    Comments [Add]    

Recommend this journal